HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results today, emphasizing the launch of its initial commercial partnerships in key U.S. markets and progress in its heart attack detection and ambulatory ECG patch initiatives. The company, which received FDA clearance for its 3D ECG technology for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, is advancing the commercialization of its cable-free cardiac monitoring platform.
The company disclosed a net loss of $4.7 million for the first quarter, an improvement from the $5.5 million loss reported in the same period last year. Research and development expenses declined year over year as HeartBeam shifted focus toward commercialization. In April 2026, the company completed a public offering that raised $11.5 million in gross proceeds, which will support its growth initiatives and market expansion efforts.
HeartBeam’s technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a standard 12-lead ECG. This platform aims to enable portable devices that can be used outside of medical facilities, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. The company holds over 20 issued patents related to its technology.
The full press release is available at https://ibn.fm/guMCF. For more information about HeartBeam and its cleared indications for use, visit https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
These results come as HeartBeam continues to build on its FDA clearances and expand its commercial footprint. The company’s focus on cable-free, 3D ECG technology positions it to disrupt traditional cardiac monitoring, potentially reducing the need for in-hospital visits and enabling earlier detection of heart conditions. The $11.5 million raised in the public offering provides additional capital to support these initiatives as HeartBeam moves from development to commercial stage.
